Phyllis Vine at MIWatch.org, a site that follows news about mental illness, asks whether drug company disclosures about payments made to doctors go far enough and whether anyone actually pays attention to such disclosures.
Vine raises the question of doctors taking part in “educational settings, including grand rounds, courses at professional conferences, or continuing education programs that pharma spends billions of dollars underwriting.”
She addresses the disproportionate number of psychiatrists who represent pharmaceutical companies and dominate the upper bracket of paid speakers. Vine also notes that, while many schools have drafted or are drafting policies about faculty-industry relations, enforcement of those policies is questionable.
